Compugen (CGEN) Net Income towards Common Stockholders (2009 - 2026)
Compugen (CGEN) posted quarterly Net Income towards Common Stockholders of $7.7 million for Q1 2026, up 7.59% year-over-year from $7.1 million in Q1 2025, and down 86.5% on a QoQ basis from $56.7 million in Q4 2025.
Analysis
Compugen (CGEN) Net Income towards Common Stockholders (2009 - 2026) Analysis & Trends
Compugen has reported Net Income towards Common Stockholders for 18 years, with the latest figure at $7.7 million in Q1 2026.
- Net Income towards Common Stockholders for Q1 2026 came in at $7.7 million, up 7.59% year-over-year; the trailing twelve-month figure through Mar 2026 was $35.9 million (up 772.34% YoY), and the FY2025 annual result was $35.3 million, up 348.35% from the prior year.
- Net Income towards Common Stockholders eased to $7.7 million in Q1 2026, from $56.7 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at $56.7 million in Q4 2025 and troughed at -$28.0 million in Q2 2023.
- A 5-year average of $1.4 million and a median of -$3.1 million in 2022 frame the typical range for Net Income towards Common Stockholders.
- The widest annual swing landed in 2023, when Net Income towards Common Stockholders tumbled 198.03%; it then jumped 1027.53% in 2025.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$3.1 million in 2022, then jumped by 414.13% to $9.7 million in 2023, then slumped by 162.98% to -$6.1 million in 2024, then jumped by 1027.53% to $56.7 million in 2025, then sank by 86.5% to $7.7 million in 2026.
- Per Business Quant data, the three most recent Net Income towards Common Stockholders figures were $7.7 million in Q1 2026, $56.7 million in Q4 2025, and -$6.9 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Compugen | 241.50 Mn | 155.89 Mn | -92,000.00 | -22.31 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -22.31 Mn |
| Mar 31, 2026 | 7.66 Mn |
| Dec 31, 2025 | 56.74 Mn |
| Sep 30, 2025 | -6.90 Mn |
| Jun 30, 2025 | -21.61 Mn |
| Mar 31, 2025 | 7.12 Mn |
| Dec 31, 2024 | -6.12 Mn |
| Sep 30, 2024 | 10.28 Mn |
| Jun 30, 2024 | -16.62 Mn |
| Mar 31, 2024 | 7.26 Mn |
| Dec 31, 2023 | 9.79 Mn |
| Sep 30, 2023 | -9.85 Mn |
| Jun 30, 2023 | -28.00 Mn |
| Mar 31, 2023 | 9.31 Mn |
| Dec 31, 2022 | -3.03 Mn |
| Sep 30, 2022 | -11.75 Mn |
| Jun 30, 2022 | 28.56 Mn |
| Mar 31, 2022 | -9.71 Mn |
| Dec 31, 2021 | -6.63 Mn |
| Sep 30, 2021 | -8.18 Mn |